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Introduction: The coexistence of autoimmune hyperthyroid disease and thyroid-stimulating hormone-secreting
pituitary adenoma is rare. The simple presumption of coincidence of these two diseases has a calculated incidence
of less than one/several hundred million, and only four cases with histological confirmation have been reported. A
rapid decrease in thyroid-stimulating hormone level after pituitary tumor removal may induce subsequent
activation of autoimmune responses against the thyroid gland. We report the first case of a sequential and
paradoxical occurrence of Graves’ disease and a thyroid-stimulating hormone-secreting pituitary adenoma.
Case presentation: A 32-year-old Japanese woman had recurrent hyperthyroidism. She had a history of Graves’
hyperthyroidism, which had been successfully treated with propylthiouracil. A head magnetic resonance imaging
showed a less enhanced area in the left lateral wing of her sella turcica. Transsphenoidal surgery was performed,
and the diagnosis was established as thyroid-stimulating hormone-secreting plurihormonal adenoma. A rapid
reduction in thyroid hormone levels was achieved, and her blood pressure was normalized after the operation.
Conclusion: Although incidental occurrence is the most probable etiology, long and repeated followup
examinations of both thyroid and pituitary gland should be performed in patients with an atypical clinical course.
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Autoimmune thyroid disease coexisting with thyroid-
stimulating hormone (TSH)-secreting pituitary adenoma
is rarely reported [1]. Postmortem study of 64 patients
with presumed primary hypothyroidism demonstrated
the presence of 12 adenomas in 10 patients, five of
which were positive for TSH staining [2]. Induced
hypothyroidism progressed to focal adenoma within
about six months in a mouse experimental model [3,4].
However, most cases describe the coexistence of
hypothyroidism and a TSH-secreting pituitary adenoma.
Only four cases of coexistence with hyperthyroidism
have been reported [5-8], and three of the four patients* Correspondence: yogawa@kohnan-sendai.or.jp
1Department of Neurosurgery, Kohnan Hospital, 4-20-1 Nagamachiminami,
Taihaku-ku, Sendai, Miyagi 982-8523, Japan
Full list of author information is available at the end of the article
© 2013 Ogawa and Tominaga; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdeveloped Graves’ disease after removal of the TSH-
secreting pituitary adenomas [5-7]. Graves’ disease
preceding the occurrence of a TSH-secreting pituitary
adenoma has never been described. We report a patient
with Graves’ disease causing recurrent hyperthyroidism
who became euthyroid, but subsequently developed a
TSH-secreting pituitary adenoma.Case presentation
A 32-year-old Japanese woman with recurrent hyperthy-
roidism was introduced to the out-patient department
of Kohnan Hospital. She had a family history of Graves’
disease. She began to feel thirst, frequent palpitations,
and body weight loss from around June 2006, and
hyperthyroidism was detected. Her serum free triiodo-
thyronine (T3) was more than 20pg/mL, free thyroxine
(T4) was 7.7ng/dL, TSH was less than the detectabled Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(normal range, less than 10%). The 24-hour uptake of
iodine-123 to the thyroid gland was 38.47% in the right
lobe and 44.16% in the left lobe (total 82.63%). A head
magnetic resonance imaging (MRI) with contrast
medium revealed thickening of the bilateral ocular
muscles, but no evident tumor in the sella turcica
(Figure 1a). The diagnosis was established as Graves’
disease, and propylthiouracil (PTU) was administered.
TRAb had fallen to the normal range, and a euthyroid
state was achieved in June 2008. However, occasional
elevation of free T3 was detected, so PTU administra-
tion was continued. Re-elevation of TSH was seen in
December 2010 (Figure 2). A head MRI revealed
abnormal findings in the sella turcica, and she was
introduced to the neurosurgical department of Kohnan
Hospital in May 2011.
On admission her blood pressure was 152/112mmHg.
Electrocardiography recorded her heart rate as 70 beats/
minute but she complained of frequent palpitations. Her
consciousness was clear, and no abnormal neurological
signs were detected. Endocrinological examinations in the
morning with oral intake of 100mg of PTU revealed free
T3 of 2.77pg/mL, free T4 of 1.09ng/dL and TSH of
2.433μIU/mL. Because of her frequent palpitations the
thyroid-releasing hormone (TRH) loading test without
discontinuing PTU was performed, which revealed no
abnormal response. All other pituitary hormones were
within the normal ranges, and head MR imaging with
contrast medium showed an area of less enhancement in
the left lateral wing of the sella turcica with a diameter of
5mm (Figure 1b), and transsphenoidal surgery was
planned under a diagnosis of TSH-secreting pituitary
adenoma.
The milky-white soft tumor was enclosed within a thin
cellulose-like membrane. Total removal was achieved in
addition to medical fixation of the cleavage with pure etha-
nol. Postoperative histological examination showed diffuse
cell arrangement with mild variation in size but without
atypism or mitosis of the nucleus (Figure 3a,b).Figure 1 Initial coronal (a) magnetic resonance imaging
showing normal appearance of the sella turcica and pituitary
gland, and follow-up coronal (b) magnetic resonance imaging
showing a less enhanced area in the left lateral wing of the
sella turcica.Immunohistochemical examination disclosed plurihormo-
nal expression of pituitary hormones including TSH-β, and
the diagnosis was established as TSH-secreting plurihor-
monal adenoma (Figure 3c,d).
Administration of PTU was discontinued from the
day of surgery. Diastolic blood pressure did not exceed
100mmHg for six days after the operation. Pituitary and
thyroid hormones were re-evaluated at 11 days after the
operation, showing free T3 was 3.31pg/mL, free T4 was
1.00ng/dL and TSH was 1.567μIU/mL. Additional TRH
loading test found no abnormal responses, and she was
discharged at 12 days after the operation. Her blood
pressure was 133/86mmHg, and palpitations had disap-
peared without medication.
Discussion
Graves’ disease induces hyperthyroidism, principally in
women aged over 20 years with an annual incidence of
0.5/1000 populations [1]. TSH-secreting pituitary aden-
oma accounts for around 1% of all pituitary adenomas
and has an annual incidence of 1–8/10,000,000 [9].
Therefore, the simple presumption of coincidence of
these two diseases has a calculated incidence of less
than one/several hundred million, and only four cases
with histological confirmation have been reported [5-8].
Three of these four cases developed after removal of the
TSH-secreting pituitary adenomas [5-7]. Our patient
presented with progressive Graves’ disease, but TSH-
secreting adenoma only developed after a euthyroid
state was achieved. There is no theoretical explanation
for these two pathogeneses. Anti-thyroid medication
administered under a misdiagnosis of Graves’ disease
may carry the risk of promotion of TSH-secreting pitu-
itary adenoma due to the positive feedback system [10].
Our patient had elevation of TRAb, excessive relative
uptake of radioactive iodine to the thyroid gland and
absence of pituitary tumor on head MRI, which satisfy
the diagnostic criteria of Graves’ disease. We could not
exclude the possibility of extremely minute pituitary
adenoma, undetectable by MRI, which might be stimu-
lated by PTU administration resulting in the sequential
occurrence of TSH-secreting adenoma. However, inci-
dental occurrence was considered to be the most pro-
bable explanation.
Diagnosis of TSH-secreting pituitary adenoma is
sometimes very complicated. Recent advances in a highly
sensitive immunoassay for TSH are expected to improve
the accuracy of diagnosis. However, if inappropriate TSH
secretion is very mild, the TSH level remains within the
normal range because of the negative feedback system to
prevent excessive secretion of thyroid hormones. Meas-
urement of the molar ratio of serum α-subunit to TSH
and assessment of response to the TRH loading test
TRAb   77.5 % 1.7 IU/L 0.3 < 0.3 <


























Figure 2 Serial evaluation of pituitary thyroid hormones. PTU: propylthiouracil, TRAb: anti-thyroid stimulating hormone receptor antibody,
TSH: thyroid-stimulating hormone.
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former have been discontinued in Japan since the beginning
of 2011. These factors should be systemically evaluated.Conclusion
We report a unique case of recurrent hyperthyroidism
preceding the occurrence of TSH-secreting pituitary aden-
oma in a patient who became euthyroid after treatment
for Graves’ disease. Although incidental occurrence is theFigure 3 Photomicrographs of the surgical specimen of the sellar tum
but without atypism or mitosis of the nucleus. Hematoxylin and eosin
immunohistochemical staining for anti-thyroid-stimulating hormone-β (c), P
Number indicates magnification of the objective lens.most probable etiology, we emphasize the importance of
repeated followup examinations of both thyroid and pitu-
itary gland in patients with an atypical clinical course.Consent
Written informed consent was obtained from the patient
for publication of this manuscript and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.or showing diffuse cell arrangement with mild variation in size
staining, original magnification × 40 (a), × 80 (b), and
RL indicates anti-prolactin (d) antibody. Original magnification × 40.
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